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Highlights 
 All tested tryptamines inhibited at least one isoenzyme. 
 IC50 values were comparable to that of clinically relevant inhibitors. 
 Members of the DALT family were strong inhibitors of CYP1A2 and CYP2D6 activity. 
 5-MeO-DALT showed in vivo inhibition against CYP1A2 activity. 
  
ABSTRACT  
New psychoactive substances (NPS) are not tested for their cytochrome P450 (CYP) inhibition 
potential before consumption. Therefore, this potential was explored for tryptamine-derived 
NPS (TDNPS) including alpha-methyl tryptamines (AMTs), dimethyl tryptamines (DMTs), 
diallyl tryptamines (DALTs), and diisopropyl tryptamines (DiPTs) using test substrates 
preferred by the Food and Drug Administration in a cocktail assay. All tested TDNPS with the 
exception of DMT inhibited CYP2D6 activity with IC50 values below 100 µM. DALTs 
inhibited CYP2D6 activity similar to paroxetine and quinidine and CYP1A2 activity 
comparable to fluvoxamine. 5-Methoxy-N,N-diallyltryptamine reduced in vivo the caffeine 
metabolism in rats consistent with in vitro results. Five of the AMTs also inhibited CYP1A2 
activity comparable to amiodarone. AMT and 6-F-AMT inhibited CYP2A6 activity in the 
range of the test inhibitor tranylcypromine. CYP2B6 activity was inhibited by 19 tryptamines, 
but weakly compared to efavirenz. CYP2C8 activity was inhibited by five of the tested TDNPS 
and three showed values comparable to trimethoprim and gemfibrozil. Six tryptamines 
inhibited CYP2C9 and seven CYP2C19 activities comparable to fluconazole and 
chloramphenicol, respectively. Nineteen compounds showed inhibition of CYP2E1 and 18 of 
CYP3A activity, respectively. These results showed that the CYP inhibition by TDNPS might 
be clinically relevant, but clinical studies are needed to explore this further. 
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1. Introduction  
 
The class of N,N-dialkylated tryptamines has been a constant element of interest within 
the context of new psychoactive substances (NPS) and this was reflected by notifications to the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), 2015). Examples of tryptamine-derived 
NPS (TDNPS) include a number of alpha-methyl tryptamines (AMTs), dimethyl tryptamines 
(DMTs), diallyl tryptamines (DALTs), and diisopropyl tryptamines (DiPTs). The recently 
published United Nations Office on Drugs and Crime World Drug Report (United Nations 
Office on Drugs and Crime (UNODC), 2014) indicated that up to July 2012 twenty-five new 
tryptamines were reported by Member States (United Nations Office on Drugs and Crime 
(UNODC), 2014). The control status varies across the globe but most of them are not yet 
placed under legislative control. Case reports on intoxications associated with 5-methoxy-N,N-
diisopropyl tryptamine (5-MeO-DiPT) were reported since the 2000s (Meatherall and Sharma, 
2003; Smolinske et al., 2005; Tanaka et al., 2006; Vorce and Sklerov, 2004; Wilson et al., 
2005). Another newer tryptamine, 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT), was 
associated with a fatal poisoning (Elliott and Evans, 2014). 
In contrast to medicinal products with marketing authorization 
(http://medicine.iupui.edu/clinpharm/ddis/main-table/), drugs of abuse (DOA) and most NPS, 
are marketed and consumed without availability of information regarding their pharmacological 
and toxicological properties (Brandt et al., 2014). One important part of safety testing is the 
evaluation of cytochrome P450 (CYP) inhibition in order to assess the potential for interactions 
when more than one drug (of abuse) is taken. Inhibition can lead to prolonged plasma 
elimination half-life and increased bioavailability, which can lead to increased risks of 
developing adverse reactions. They can cause increased number and/or duration of 
hospitalization (Palleria et al., 2013). A systematic screening of methylenedioxy-derived 
designer drugs showed that these drugs are inhibitors of the main CYP isoenzymes, some with 
IC50 values in the range of clinically relevant inhibitors (Dinger et al., 2014c).  
The present study aimed to evaluate TDNPS for their inhibition potential towards 
relevant CYP isozymes. For this purpose, a two cocktail approach (Dinger et al., 2014a; Dinger 
et al., 2014b) was used to determine the inhibitor concentrations which reduced the enzyme 
activity by 50% (IC50 value). In addition, the in vitro inhibition potential against CYP1A2 of 5-
MeO-DALT was confirmed in vivo using rats and caffeine as test substrate.  
 
 
2. Materials and methods 
 
2.1. Chemicals and reagents 
 
Alpha-naphthoflavone, amodiaquine 2HCl, caffeine solution 1 mg/mL, coumarin, 
deethyl amodiaquine, dextrorphan HBr, diclofenac, 5-hydroxy coumarin, isocitrate, isocitrate 
dehydrogenase (IDH), omeprazole, sulfaphenazole, superoxide dismutase (SOD), 
trimethoprim, and verapamil HCl were obtained from Sigma-Aldrich (Steinheim, Germany), 
bupropion HCl and 4-hydroxy bupropion HCl from GlaxoSmithKline (Munich, Germany), 4-
hydroxy diclofenac from Pombiotech (Saarbrücken, Germany), phenacetin and 
dextromethorphan from Roche (Grenzach, Germany), fluconazole and sertraline from Pfizer 
(Berlin, Germany), paracetamol from Benchemie (Munich, Germany), tranylcypromine from 
Röhm Pharma (Darmstadt, Germany), quinidine from Chininfabrik Buchler (Braunschweig, 
Germany), clomethiazole from AstraZeneca (Wedel, Germany), chlorzoxazone from Cilag 
(Schaffhausen, Swiss), 6-hydroxy chlorzoxazone from Toronto Research Chemicals (Toronto, 
Canada) and delivered from LGC Standard (Wesel, Germany), 5-hydroxy omeprazole from 
@rtMolecule (Poitiers, France) and delivered from IBL international (Hamburg, Germany), 
dimethyltryptamine from THC Pharma (Frankfurt, Germany), NADP+ from Biomol (Hamburg, 
Germany), formic acid (mass spec grade) and testosterone from Fluka (Neu-Ulm, Germany), 
paraxanthine solution 1 mg/mL in methanol from LGC Standards, theobromine and 
theophylline from Knoll AG (Ludwigshafen, Germany), acetonitrile and methanol (all LC-MS 
grade), and all other chemicals from VWR (Darmstadt, Germany). All non-scheduled 
tryptamines were prepared following procedures published previously (Brandt et al., 2012; 
Young, 1958). Pooled human liver microsomes (pHLM, 20 mg microsomal protein/mL, 400 
pmol total CYP/mg protein, 25 donor pool, mixed gender, average age 55 years, one Hispanic, 
two African Americans and 22 Caucasians) were obtained from Gentest and delivered from 
Corning (Amsterdam, Netherlands). After delivery, the microsomes were thawed at 37 °C, 
aliquoted, snap-frozen in liquid nitrogen, and stored at -80 °C until use. Whatman 903 ﬁlter 
paper cards (WHA10334885) were from GE Healthcare (Dassel, Germany). S-Monovette 
mixing aid (1.6 mg EDTA/mL blood) and multi adapter from Sarstedt (Nümbrecht, Germany), 
BD Microlance 3, sterile needle (0.5 x 25 mm) from BD Medical Systems (Drogheda, Ireland). 
Indicator silica gel pearls KC were obtained from NeoLab Migge (Heidelberg, Germany). 
 
2.2. LC-HR-MS/MS apparatus for in vitro cocktail incubations 
 
All analytical features associated with instrumentation have been described in detail 
elsewhere (Dinger et al., 2014a). Briefly, a Thermo Fisher Scientific (TF, Dreieich, Germany) 
Aria Transcend TLX-I HTLC, together with a TF Accela 1250 pump, a TF HTC PAL 
autosampler, and a valve interface module were used with built-in switching valves, all 
controlled by the TF Aria software version 1.6.3. It was coupled to a TF Q-Exactive equipped 
with a heated electrospray ionization source (HESI-II). The gradient elution was performed on 
a TF Accucore RP-MS (150 x 2.1 mm, 2.6 µm) column using water containing 0.02% (v/v) 
formic acid pH 3.1 (eluent A) and acetonitrile containing 0.1% (v/v) formic acid (eluent B) and 
a flow rate of 600 µL/min. The injection volume for all samples was 10 µL. 
The MS conditions were as follows: HESI-II, positive and/or negative mode; sheath gas, 
nitrogen at a flow rate of 60 arbitrary units (AU); auxiliary gas, nitrogen at a flow rate of 20 
AU; vaporizer temperature, 350 °C; spray voltage, 3.00 kV positive and 4.00 kV negative; ion 
transfer capillary temperature, 380 °C; and S-lens RF level, 50.0. 
A targeted single ion monitoring experiment with mass spectrometric multiplexing (msx) 
and inclusion list was performed using the protonated or deprotonated ions of the metabolites. 
For the detection of O-deethyl phenacetin and N-deethyl amodiaquine, fragment ions obtained 
from in-source collision induced dissociation with 25 eV were used. 
The scan parameters were as follows: microscan, 1; resolution, 17,500; AGC target, 1e6; 
maximum injection time, 250 ms; msx count, 5; isolation window, 1 m/z; scan range, m/z 100-
400. The scan parameters were the same for positive and negative mode.  
TF Xcalibur 2.2 software was used for data handling. The settings for automated peak 
integration were as follows: peak detection algorithm, ICIS; smoothing, 7; area noise factor, 5; 
and peak noise factor, 10. 
 
2.3. Preparation of stock solutions and spiking solutions for in vitro inhibition experiments 
 
The specific substrates, their metabolites, and model inhibitors were used and prepared 
in accordance to Dinger et al. (Dinger et al., 2014b). All stock solutions (10 mM) for the test 
inhibitors (tryptamines) were prepared in water/methanol 9/1 (v/v) with the exception of 4,5-
ED-DALT, 5-F-2-Me-DALT, 6-F-DALT (water/methanol 8/2 (v/v)), 4-HO-DiPT, 5-MeO-2-
Me-DiPT, 5-MeO-DiPT, 5-MeO-2-Me-DMT (water/methanol 1/1 (v/v)). These stock solutions 
were serially diluted with phosphate buffer for the incubations. 
 
 
 
 
2.4. Conditions for the cocktail incubations 
 
The conditions were already described elsewhere (Dinger et al., 2014b). Briefly, 
microsomal incubations were performed at 37°C for 15 min with 0.2 mg/mL pHLM and the 
test substrates, split in two cocktails. Incubation time and protein content were in the linear 
range of product formation for all incubated enzymes and corresponding substrates. Cocktail A 
contained 12 µM of phenacetin, 1.1 µM of coumarin, 3.5 µM of diclofenac, 8.5 µM of 
dextromethorphan, and 86 µM of testosterone, and cocktail B 30 µM of bupropion, 2 µM of 
amodiaquine, 21 µM of omeprazole, and 20 µM of chlorzoxazone so that all concentrations 
were at or below the Km value (U.S.Department of Health and Human Services et al., 2006). 
Besides enzymes and substrates, incubation mixtures (final volume: 50 µL) consisted of 90 
mM phosphate buffer (pH 7.4), 5 mM Mg2+, 5 mM isocitrate, 1.2 mM NADP+, 0.5 U/mL 
isocitrate dehydrogenase and 200 U/mL superoxide dismutase. Reactions were started by 
addition of the ice-cold microsomes and stopped with 50 µL of ice-cold acetonitrile containing 
the internal standards (IS, diphenhydramine 0.1 µM, trimipramine 0.1 µM, and ibuprofen 100 
µM). The incubation mixtures were centrifuged for 5 min at 14,000 g, 40 µL of both 
supernatants (cocktail A and B) were pooled, transferred to an autosampler vial, and 10 µL 
were injected onto the LC-HR-MS/MS apparatus for analysis under the conditions described 
above. 
 
2.5. Prescreening and determination of IC50 values  
 
2.5.1. Prescreening 
According to Dinger et al. (Dinger et al., 2014c), the general inhibition potential of the 
TDNPS was tested using the cocktails incubated with 100 µM of each TDNPS (structures 
given in Fig. 1) in triplicates. In addition to these samples, control samples without inhibitor, 
positive control samples with model inhibitors (20 µM), and interfering samples were also 
prepared in triplicates. For the interfering samples, control samples without inhibitor were 
incubated and the reaction was terminated with ice-cold acetonitrile containing the IS and the 
tested TDNPS. For sample evaluation, the metabolite formation in the incubation sample was 
compared to the formation in the control sample. Every inhibition sample was compared with 
every control sample (n = 3 each). 
 
2.5.2. Determination of IC50 values 
 
According to Dinger et al. (Dinger et al., 2014c), the IC50 values were determined in 
duplicate for TDNPS, showing more than 50% inhibition of the activity of one or more 
isoenzymes. The TDNPS were used at ten different concentrations (0.01, 0.05, 0.1, 1, 10, 50, 
100, 200, 400, 800 µM). Control, positive control, and interfering samples were also prepared 
as described above. The IC50 values were calculated by plotting the metabolite formation 
(relative to the control sample) over the logarithm of the TDNPS (inhibitor) concentration 
using GraphPad Prism 5.00 (GraphPad Software, San Diego, CA, USA). Relative metabolite 
formation was calculated by division of every inhibition sample with every control sample (n = 
2 each). Statistic evaluation of the IC50 values were also performed using GraphPad Prism 5.00. 
 
2.6. In vivo CYP1A2 inhibition testing for 5-MeO-DALT 
 
2.6.1. LC-MS/MS apparatus 
 
All samples were analyzed using a TF TSQ Quantum Access mass spectrometer coupled 
to a TF Accela UHPLC system consisting of a degasser, a quaternary pump, and an 
autosampler. Gradient elution was performed on a TF Accucore RP-MS column (150×2.1 mm, 
2.6 μm). The mobile phase consisted of water plus 0.01% formic acid (eluent A) and methanol 
plus 0.01% formic acid (eluent B). The flow rate was set to 700 μL/min, and the gradient was 
programmed as follows: 0–1.5 min to 85% A, 1.5–2.5 min to 70% A, 2.5–3.1 min hold, 3.1–4.5 
min to 60% A, 4.5–6.5 min to 5% A, 6.5-7.5 min hold, 7.5-7.6 back to 85% A and hold till 10 
min. 
The MS conditions were as follows: atmospheric pressure chemical ionization (APCI), 
positive mode, sheath gas, nitrogen at a flow rate of 40 arbitrary units; auxiliary gas, nitrogen at 
flow rate of ten arbitrary units; collision gas, argon; vaporizer temperature, 300 °C; discharge 
current, 4.0 μA; ion transfer capillary temperature, 250 °C; and capillary offset, 35 V. 
The mass spectrometer was operated in the timed multiple-reaction monitoring (MRM) 
mode with the following settings: collision pressure, 1.5 mTorr; isolation width Q1, 0.7 units; 
and scan time, 1 s. Transitions and their particular settings, collision energy, and tube lens were 
optimized for each analyte. All MRM transitions, collision energies, tube lens settings, and 
retention times used for the given analytes are summarized in Table 1. For data evaluation, TF 
Xcalibur 2.1.0 were used to obtain peak areas. The settings were as follows: peak detection 
algorithm ICIS; smoothing, 5; and area-to-noise factor, 5, peak-to-noise factor 10. GraphPad 
Prism 5.00 was used for statistical analysis. 
 
2.6.2. Preparation of stock solutions, calibration standards, and control samples for validation 
of the LC-MS/MS method 
 
Two different methanolic stock solutions (1.0 mg/mL) of caffeine were used. For 8-
chlorotheophylline, fluvoxamine, 5-MeO-DALT, theobromine, and theophylline, methanolic 
solutions (1.0 mg/mL) were prepared and for paraxanthine a standard methanolic solution (1.0 
mg/mL) was used. 
Working solutions (0.01 and 0.1 mg/mL) of analytes were prepared in methanol by 
dilution from each stock solution. The spiking solutions for calibration standards and quality 
control (QC) samples were prepared by adding the appropriate amount of the corresponding 
stock or working solution to volumetric flasks to obtain the corresponding plasma or spot 
concentration. Calibration standards were prepared freshly every day spotting 10 μL of the 
corresponding spiking solution to a 30 µL blank dried blood spots (DBS). QC samples were 
prepared at two different concentrations (LOW and HIGH) in the same way than the calibration 
standards and additionally by spiking fresh whole blood with the solution, ten times higher than 
the recommended concentration, before spotting. 
 
2.6.3. Method validation for caffeine quantification 
 
The method was validated as recommended for single case analysis, including 
selectivity, recovery, matrix effects, process efficiency, linearity, accuracy and precision, and 
limit of quantification (Peters et al., 2007). Additionally, it was evaluated whether blank DBS 
could be used to prepare calibrators and QC samples. Therefore, blank rat blood was spiked at 
low and high concentration before spotting and blank DBS were spiked with the corresponding 
concentrations (n=6, each). The peak areas of both sample sets were compared using a two-
tailed unpaired t-test using Graphpad prism. Selectivity was determined by analyzing six blank 
DBS in multiple reaction monitoring mode (MRM) to check for signals that might interfere 
with caffeine or the IS. In addition, two zero samples (blank spot including IS) were analyzed. 
Matrix effects were determined according to Matuszewski et al. (Matuszewski et al., 1998) 
analyzing six samples for each sample set at low and high concentration. Sample set 1 
consisted of neat standard solution, set 2 of extracted blank DBS spiked after extraction, and set 
3 of the extracted spiked DBS. The calibration at six different concentrations (0.05, 1, 3, 5, 7, 
10 mg/L) was performed in duplicate and analyzed as described above. The regression line was 
calculated using a first-order polynomial weighted (1/x2) least-squares model. Six QC samples 
at low (0.1 mg/L) and high (9 mg/L) concentrations were analyzed and determined based on 
calibration curves. Accuracy was calculated in terms of bias as the percent deviation of the 
mean calculated concentration at each concentration from the corresponding theoretical 
concentration. Precision was calculated as the relative standard deviation (RSD). The lower 
limit of quantification (LLOQ) of the method was defined as the concentration of the QC low 
and was checked for the acceptance criterion of a signal-to-noise (S/N) ratio of >10. 
Theobromine, theophylline, fluvoxamine and 5-MeO-DALT, and paraxanthine were 
qualitatively monitored to exclude interferences.  
 
2.6.4. Rat plasma sampling  
 
Blood samples from male Wistar rats (Charles River, Sulzfeld, Germany) were taken 
after administration of the compounds by gastric intubation using an aqueous suspension for 
toxicological diagnostic reasons according to the corresponding German law. A single 10 
mg/kg body mass (BM) dose of caffeine was administered to all rats (n=6). In addition to 
caffeine, a 6 mg/kg BM dose of fluvoxamine and 0.6 mg/kg BM of 5-MeO-DALT were 
administered in parallel to two rats, respectively. Doses were calculated according to known 
human doses (De Kesel et al., 2014; FachInfo Service (www.fachinfo.de), 2013; Shulgin and 
Shulgin, 2004) using a simple factor approach, considering the species differences in 
pharmacokinetic parameters (clearance, volume of distribution) (Sharma and McNeill, 2009). 
Blood samples were taken at eight different time points (0, 1, 2, 3, 4, 5, 6, 24 h after 
administration) from lateral tail vein using EDTA tubes combined with a sterile needle. A 30-
µL aliquot of whole venous blood was directly spotted on Whatman paper cards for DBS as 
already done by Wickremsinhe (Wickremsinhe, 2015). Blank blood samples for calibration 
standards were collected before drug administration and spotted directly. DBS were stored in 
exsiccator with silica gel pearls as drying agent at room temperature until analysis.  
 
2.6.5. Extraction procedure for DBS 
 
The DBS were extracted according to de Kesel et al. (De Kesel et al., 2014). In contrast, 
the whole DBS was punched and divided in 4 parts. These parts were extracted with 280 µL of 
a mixture of methanol and water 80/20 (v:v) containing 0.01% of formic acid and 1 mg/L of 8-
chlorotheophylline as internal standard (IS) for 10 minutes on a rotary shaker. Afterwards, the 
samples were centrifuged for 10 min at 14680 rpm and 200 µL of the upper phase was 
transferred to a glass vial. The solvent was evaporated under a stream of nitrogen at 70°C and 
reconstituted in 100 µL of solvent A. Ten microliters of this extract were injected onto the LC-
MS/MS system. 
 
2.6.7. Determination of in vivo CYP1A2 inhibition by 5-MeO-DALT 
 
The inhibition effects on the metabolism of caffeine were determined by calculating the 
kinetic constants area under the plasma concentration/time curve (AUC), Cmax, and tmax for all 
groups. The AUC was calculated using the trapezoidal rule. The Bateman equation (equation 1) 
was used for calculating cmax and tmax. 
 
C = f * D/V*ka/(ka-ke) * (exp.
-ke*t-exp.-ka*t)       (1) 
 
 
3. Results and discussion 
 
3.1. Prescreening and determination of IC50 values 
 
For all incubations, protein and time courses were tested for all isoenzyme/substrate 
reactions, and incubation conditions were chosen accordingly. The protein concentration of 0.2 
mg/mL was sufficient for analyzing the specific substrate metabolites and were not expected to 
show non-specific protein binding (Baranczewski et al., 2006). In addition, the Food and Drug 
Administration (FDA) guidance advised a protein concentration below 1 mg/mL for in vitro 
CYP inhibition studies (U.S.Department of Health and Human Services et al., 2006). 
Microsomes were used instead of hepatocytes or liver tissues, because the enzyme 
concentrations were much higher in microsomes (Lu, 2014). Thus, smaller sample amounts 
could be used reducing the risk of unspecific protein bindings. Suitable incubation conditions 
were monitored incubating positive control samples with a mixture of the model inhibitors (20 
µM) of each isoenzyme (Dinger et al., 2014b). Analytical interferences such as ion suppression 
or enhancement caused by co-eluting TDNPS were tested using incubated control samples (no 
inhibitor). The incubation was terminated with acetonitrile containing the internal standards and 
the corresponding TDNPS (Dinger et al., 2014a). These samples were prepared to avoid false 
positive inhibition results in case of ion suppression or negative results in case of ion 
enhancement. This was necessary because only the specific metabolites were monitored by the 
analytical method and possibly co-eluting TDNPS were not detected. All control samples 
(without inhibitor) were compared to each incubation sample (n = 3 each for prescreening, n = 
2 each for IC50 value determination).  
As shown in Fig. 2, DMT was the only compound without inhibition of any isoenzyme 
activities. All others showed inhibition on CYP2D6 resulting in less than 50% activity in the 
prescreening experiment. All tested members of the DALT family reduced the CYP1A2 
activity to less than 20% activity. Analytical interferences could be excluded. All isoenzymes 
were inhibited by the specific inhibitors in the positive controls. These kind of prescreening 
experiments were performed to gain a general overview of the inhibition potential for the tested 
drugs. A tryptamine concentration of 100 µM was chosen because at that concentrations, no or 
only slight inhibition could be considered as clinically irrelevant. Clinically relevant inhibitors 
showed IC50 values of about 100 µM (Bertelsen et al., 2003; Brosen et al., 1993; Burt et al., 
2010; Ewald and Maurer, 2008; Kobayashi et al., 1998; Niwa et al., 2005; Park et al., 2003; 
von Moltke et al., 1998; Wang et al., 2002; Xu and Desta, 2013). Therefore, the IC50 values 
were only determined for TDNPS that showed inhibition of more than 50%. Performing such 
pre-experiments was helpful to save time and costs if isoenzymes of only one of both cocktails 
or no isoenzymes were inhibited. Thus, the IC50 values of DMT were not determined and for 2-
Me-AMT, only cocktail A had to be incubated. For all other tested TDNPS, both cocktails were 
incubated because at least one isoenzyme each was inhibited during the prescreening. 
As can be seen in Table 2, all tested TDNPS showed inhibition against at least one isoenzyme 
of the nine tested with IC50 values comparable to corresponding known clinically relevant 
inhibitors. However, to assess the clinical relevance based on IC50 values of known drugs, the 
plasma levels of these drugs and the tested TDNPS have to be considered (given in Table 2). 
Plasma concentrations of the tested tryptamines are only published for AMT and 5-MeO-DiPT 
(0.9-7.5 µM, 0.14-1.7 mg/mL). Common dosage levels associated with a range of psychoactive 
tryptamines were described to vary considerably although ranges between 5-60 mg were not 
uncommon (Shulgin and Shulgin, 1997). For most of the tested tryptamines, no data were 
available in the published literature but similar doses and therefore, similar plasma 
concentrations were considered acceptable (in the range of 0.5-9 µM). All tested AMTs, all 
DALTs, 5-MeO-2-Me-DMT, and 4-HO-DiPT showed inhibition against CYP1A2 activity. All 
DALTs showed IC50 values against CYP1A2 activity below 1 µM, being in the same range as 
the strong inhibitor fluvoxamine (IC50 value of 0.2 µM). Compared to the probe inhibitor 
alpha-naphthoflavone, the values were up to 10 times higher. The assumed plasma levels were 
in the same range as those for fluvoxamine. Based on these data, clinical relevance of the 
CYP1A2 inhibition by DALTs could not be excluded. This inhibition could especially be 
relevant for co-administered drugs such as clozapine, which were exclusively metabolized by 
CYP1A2. Severe clozapine intoxications caused by CYP1A2 inhibition were known as 
problem under the treatment with clozapine (Heeringa et al., 1999; Pinninti and de, 1997; Van 
Strater and Bogers, 2012). Five of the tested AMT showed values below 50 µM and the other 
inhibitors showed higher IC50 values (105-336 µM). For the AMTs, clinical relevance could 
also not be excluded although the values were higher than for the DALTs. However, they were 
below the range of the IC50 value of amiodarone (IC50 value of 86 µM), a known CYP1A2 
inhibitor, with plasma levels of the AMTs comparable with that of amiodarone. Comparing the 
structural properties and the IC50 values, it seemed that the N,N-diallyl group enhanced the 
inhibition potential in contrast to the alpha-methyl, dimethyl, or diisopropyl groups. However, 
the substituents in positions 2, 5, 6, or 7 enhanced the potential significantly compared to 
DALT itself, but no difference between these substituents could be observed. In contrast to that 
family, the different substituents of the AMTs influenced the inhibition potential. Methylation 
in position 5 enhanced the potential in contrast to position 2 resulting in a higher IC50 value of 
138 µM in contrast of 22 µM for 5-Me-AMT. The derivative with 2-methylation and 5-
fluorination (IC50 value of 126 µM) increased significantly the inhibition potential in contrast to 
the single substituted analogues (IC50 value of 170 µM). In the case of CYP2A6, AMT and 6-
F-AMT showed the highest inhibition with IC50 values of 3.2 and 2.7 µM, respectively. These 
values were in the range of the value of the FDA-recommended specific inhibitor 
tranylcypromine (IC50 value of 0.4 µM). Plasma levels for tranylcypromine were described to 
be lower than those for tryptamines in fatal cases. These data should not be overestimated, as 
nothing was known about common users’ plasma concentrations. However, clinical relevance 
cannot be excluded. 2-Me-AMT, 4-MeO-AMT, 5-F-AMT, 5-Cl-AMT, 5-Me-AMT, 7-Me-
AMT, 4,5-ED-DALT, and 4-HO-DiPT inhibited also CYP2A6 activity, but with values 
between 74 and 450 µM, 100 times higher than that of tranylcypromine, so clinical relevance 
could not be assumed. CYP2B6 activity was inhibited by 19 of the tested TDNPS with IC50 
values between 0.8 and 377 µM with 5-MeO-DALT as the strongest inhibitor. The value of 5-
MeO-DALT was in the same range as the in vitro test inhibitor sertraline and the clinically 
relevant inhibitor efavirenz. As plasma levels of 5-MeO-DALT were lower than that of 
efavirenz, the concentrations needed for inhibition should only be reached in overdose cases. 
However, clinical relevance cannot be excluded as this tryptamine showed lower IC50 values 
than efavirenz. However, interaction could be relevant for polydrug users under substitution 
with methadone, which is metabolized by CYP2B6 to EDDP, resulting in increased methadone 
levels (Kharasch et al., 2015). For the other TDNPS, comparably weak inhibition with values 
higher than 25 µM (5-F-2-Me-AMT, 7-Me-AMT, 5-F-DALT, 5-F-2-Me-DALT, 5-Cl-DALT, 
5-Br-DALT, 6-F-DALT, 4,5-ED-DALT, ) or higher than 100 µM (AMT, 5-Cl-AMT, 5-Me-
AMT, 6-F-AMT, DALT, 5-Me-DALT, 7-Me-DALT, 5-MeO-2-Me-DMT, 4-HO-DiPT, 5-
MeO-2-Me-DiPT) could be shown and the clinical relevance of these inhibitions seemed to be 
negligible. CYP2C8 activity was inhibited by five  
of the tested tryptamines (5-F-2-Me-DALT, 5-Cl-DALT, 5-Br-DALT, 6-F-DALT, 4,5-ED-
DALT) and the value of 4,5-ED-DALT was the lowest with 17 µM. This value was in the 
range of the specific test inhibitor trimethoprim (IC50 value of 17 µM) and the value of 6-F-
DALT was in the range of that of gemfibrozil (IC50 value of 91 µM), a known inhibitor (Niemi 
et al., 2003). The described plasma level of trimethoprim was also comparable to that of the 
tryptamines, so a clinical relevance could not be excluded for 4,5-ED-DALT. In contrast, the 
plasma levels of gemfibrozil were described as much higher than that of the tryptamines, so 
relevance cannot be assumed, although the IC50 values were in the same range. All other 
compounds showed a weaker inhibition with values of about 100 µM. Nine compounds 
inhibited the CYP2C9 activity with IC50 values between 23 and 159 µM with 5-Br-DALT and 
5-Cl-DALT as strongest inhibitors. Six of these values were comparable to the value of 
fluconazole (IC50 value of 30.3 µM), a clinical relevant CYP2C9 inhibitor 
(http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). Concerning the specific inhibitor 
sulfaphenazole (IC50 value of 0.4 µM), the values were hundred times higher (Dinger et al., 
2014b). The plasma levels of all TDNPS were lower than those of fluconazole and thus, 
clinical relevance of the inhibition of CYP2C9 activity by these TDNPS seemed to be 
improbable. CYP2C19 activity was inhibited by AMT, five members of the DALT family, and 
4-HO-DiPT with values between 33 and 88 µM. These values were in the range of the IC50 
value of 32 µM of chloramphenicol, a known inhibitor with clinical relevance (Hafner et al., 
2008; Koup et al., 1978) and slightly above the probe inhibitor fluconazole (IC50 value of 17 
µM). Concerning the plasma levels, the levels of fluconazole and chloramphenicol were much 
higher than those of the tryptamines (4.9-31 µM), so a clinical relevance of these inhibition 
potentials seemed also improbable. The other nine tryptamines showing CYP2C19 inhibition 
had values above 100 µM and these values could be seen to be not really clinically relevant. As 
already seen during the prescreening experiments, CYP2D6 was inhibited by all tested 
tryptamines with the exception of DMT. All determined IC50 values were below 100 µM. The 
DALTs showed the strongest inhibition with values below 5 µM with the exception of 5-MeO-
DALT (13 µM) and were in the same range as those of the well-known clinically relevant 
inhibitors paroxetine and fluoxetine (IC50 values of 2.85 µM and Ki value of 8.2 µM). The IC50 
values of 5-F-2-Me-DALT, 6-F-DALT, and 7-Me-DALT were even comparable with the value 
of the CYP2D6 probe inhibitor quinidine (0.1 µM). Three of the AMTs and one of the tested 
DiPTs also inhibited CYP2D6 activity in the same range as the known inhibitors. The plasma 
levels of all tested TDNPS were in comparable ranges as those of paroxetine and fluoxetine. 
Therefore, the inhibition potential of these drugs might be of clinical relevance. The inhibition 
of this isoenzyme could be critical because a lot of therapeutic and abused drugs are 
metabolized by this isoenzyme (http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). The 
therapeutic effect of prodrugs such as risperidone or tramadol could not be effective. 
Antidepressive such as amitriptyline, clomipramine, venlafaxine or neuroleptics such as 
haloperidol are also metabolized by this isoenzyme. Inhibition of their metabolism could result 
in increased plasma levels and intoxication symptoms. Comparing the structural properties and 
the determined IC50 values, it seemed that the IC50 values increased from diallyl, over alpha-
methyl and dimethyl to diisopropyl-substituted tryptamines. This could be observed for all 
tested tryptamines. The second correlation was that the IC50 values decreased from drugs with 
methyl or fluoro substituents in position 5 to those with chloro substituents. In contrast, the 
substitution by methyl or fluoro group influenced the inhibition potential in the same range. 
Substitution in position 6 and 7 by a fluoro or methyl group prefer the CYP2D6 inhibition by 
DALTs in contrast to AMTs. CYP2E1 activity was reduced by 19 tryptamines with 5-Me-
DALT, 5-MeO-DALT and 5-MeO-2-Me-DMT showing the highest potential with IC50 values 
of 11, 20, and 20 µM, respectively. Only these IC50 values were comparable with the values of 
the probe inhibitor clomethiazole (IC50 value of 10.9 µM). (Dinger et al., 2014b; Gebhardt et 
al., 1997). The IC50 values and the plasma concentrations were in the same range, so a clinical 
relevance of the CYP2E1 inhibition could not be excluded for these three compounds. 
However, the values of the other tryptamines were much higher but a clinical relevance could 
also not be excluded. Eighteen of the tested TDNPS showed also inhibition against CYP3A 
activity. All DALTs showed inhibition potentials (IC50 values 31-114 µM) in the range of the 
protease inhibitor saquinavir (IC50 value of 11.5 µM), the calcium channel blocker verapamil 
(IC50 value of 22 µM)., the probe inhibitor for CYP3A, and the time-dependent inhibitor 
clarithromycin (IC50 value of 116 µM). The clinical relevance of verapamil inhibition is well-
known. For example, Kandavar and Sander described a multi-organ failure caused by co-
administration of the CYP3A substrate atorvastatin and the CYP3A inhibitor verapamil 
(Kandavar and Sander, 2010). In addition, the IC50 values of 4-MeO-AMT and 4-HO-DiPT 
were in the range of clarithromycin. The clinical relevance of CYP3A4 inhibition by 
clarithromycin is well-known. For example, Gasche et al. (Gasche et al., 2004) described a 
narcotic syndrome of a patient under therapeutic codeine doses because of the co-
administration of clarithromycin inhibiting the CYP3A4-catalyzed detoxification to 
norcodeine. Other factors fortified the effect. As the plasma levels of saquinavir and verapamil 
were in the same range as that of the tryptamines, clinically relevant interaction could not be 
excluded. In contrast, the therapeutic plasma levels of the antibiotic clarithromycin were much 
higher than for the tested TDNPS with the exception of poisoning cases. Because of these data, 
the inhibition potentials of these drugs against CYP3A activity could be assessed as weak. 
Concerning the structural properties and the IC50 values of the DALT family, it seemed that 
introduction of substituents in 5 or 6 positions enhanced the inhibition potential. The values of 
DALT itself and the substituted analogues, with the exception of 5-Cl-DALT and 5-MeO-
DALT, were significantly different. Substitution of both positions with methylenedioxy bridge 
showed the highest effect (Dinger et al., 2014c). 
 
 
 
3.3. In vivo inhibition potential of 5-MeO-DALT 
 
3.3.1. Quantification of caffeine 
 
For determination of the corresponding caffeine concentrations in rat blood by LC-
MS/MS, DBS were prepared to save blood volume. Besides common validation parameters, the 
usage of blank DBS for preparing calibrators and QC samples was evaluated. Using a two-
tailed unpaired t-test, the peak areas of sample set 1 (whole blood spiked before spotting) and 
set 2 (blank DBS spiked after spotting) at low and high concentration were not significantly 
different (p<0.05). The method was selective for caffeine as well as for the IS and no 
interfering peaks could be detected in the MRM mode. Results for recovery, matrix effect, 
process efficiency, accuracy, and precision are summarized in Table 3. The calibration curves 
were linear and the back-calculated calibrators were within the acceptance criteria. The LLOQ 
was consistent with the lowest calibrator and within the required acceptance criteria. The used 
blood volume for spotting was 30 µL. According to Wickremsinhe (Wickremsinhe, 2015) there 
was no difference between 10, 20 or 30 µL spot volume. Thus, 30 µL was used for more 
sensitive determination of caffeine. The whole spot was punched avoiding variations in spread 
area caused by different hematocrit values (Wickremsinhe, 2015). 
 
3.3.2. Determination of in vivo inhibition potential of 5-MeO-DALT 
 
According to Kot and Daniel, CYP1A2 metabolized over 80% of caffeine in humans 
and rats and only the metabolite profile differed (Kot and Daniel, 2008). The study design was 
chosen in accordance to the FDA guidance (U.S.Department of Health and Human Services et 
al., 2006). To monitor also a rapidly reversible inhibition, the substrate and the inhibitor were 
given simultaneously because the mode of inhibition was not known for 5-MeO-DALT. As 
positive control, the known CYP1A2 inhibitor fluvoxamine was tested under the same 
conditions. Results are summarized in Table 4. The control group (only caffeine 
administration) showed the lowest AUC of the plasma concentration time curve with 36 
h*mg/L, in good correlation with described values (Latini et al., 1978). For the positive control 
group, the AUC was about three times higher than for the control group, proving the study 
design. The AUC of test group was 307 h*mg/L. The control group showed the lowest Cmax 
value of 4.2 mg/L. For the other two groups, the value increased five times compared to the 
control group. Tmax was for all groups in the same range (1.9 – 2.6 h). The tested kinetic 
parameters of caffeine increased for the positive and test group instead of the control group as 
expected according to the in vitro data. Hence, in vivo data seemed to confirm the in vitro data 
for 5-MeO-DALT. However, further studies with larger groups are needed to confirm this 
observation.  
 
4. Conclusions 
 
The presented study showed that with the exception of DMT all tested TDNPS showed 
more or less inhibition potential against the various CYP isoforms. Because of this inhibition 
potential in the range of clinical relevant inhibitors and similar plasma concentrations, the 
following drugs might cause clinically relevant interactions with the given CYPs: CYP1A2, 4-
MeO-AMT, 5-F-2-Me-AMT, 5-Cl-AMT, 6-F-AMT, 7-Me-AMT, all DALTs; CYP2A6, AMT, 
6-F-AMT; CYP2D6, AMT, 5-F-AMT, 5-F-2-Me-AMT, 5-Cl-AMT, all DALTs, 4-HO-DiPT; 
CYP2E1, 5-Me-DALT, 5-MeO-DALT, 5-MeO-2-Me-DALT; CYP3A, 5-F-2-Me-DALT, 5-Cl-
DALT, 5-Br-DALT, 5-Me-DALT, 6-F-DALT. 
Thus, these TDNPS could change the pharmacokinetics, namely the plasma levels and 
the corresponding effects of co-administered therapeutics or NPS. Prodrugs such as tramadol, 
tilidine, or risperidone, mainly metabolized by one or two isoenzyme, could lose their potency, 
if bioactivation was blocked (Mannheimer et al., 2008; Stamer et al., 2007; Wustrow et al., 
2012). Neuroleptics such as clozapine or haloperidol could accumulate in plasma and lead to 
toxic concentrations (Murray, 2006). The inhibition of CYP2D6 and CYP3A4 could be 
important because many endogenous compounds and xenobiotics were metabolized by these 
two isoenzymes (http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). However, it should 
be kept in mind that clinical cases or studies would be desirable to finally assess the risks 
associated with drug-drug interactions. 
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Legends to the Figures  
Fig. 1. Structures of the tested tryptamines. Eponymous structural parts are given in red. 
 
Fig. 2. Prescreening results (n = 3 each) using 100 µM each of TDNPS arranged in the order used 
in Table 1. Percentage of activity was the percentage of metabolite formation in relation to 
control sample (100%), incubated without inhibitor. 
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Table 1 
Compounds, precursor ions, monitored fragment ions for MRM, collision energies, and tube lens 
settings of caffeine and its metabolites, fluvoxamine, 5-MeO-DALT and the internal standard 
Compounds 
Precursor 
ions, u 
Fragment ion 1 Fragment ion 2 
 
[M+H]+ [M+H]+ 
Collision 
energy, V 
Tube 
Lense, V 
[M+H]+ 
Collision 
energy, V 
Tube 
Lense, V 
Caffeine 195 110 22 70 138 18 70 
Fluvoxamine 319 71 15 95 258 11 95 
5-MeO-DALT 271 159 31 42 174 19 42 
Paraxanthine 181 124 18 72    
Theobromine 181 138 18 72    
Theophylline 181 124 18 72    
8-
Chlorotheophylline 
(IS) 
215 158 20 69    
 
Table 2 
Test compounds, reference plasma concentrations, IC50 values of TDNPS and known inhibitors, and inhibited CYP enzyme activities. 
Plasma concentrations in µM were calculated from the published data in mg/L. Plasma concentrations given in italic were assessed 
according to the structural related compounds AMT and 5-MeO-DiPT. Probable clinically relevant IC50 values are given in bold.  
Test compounds 
Reference plasma 
concentrations 
IC50 values on CYP, µM 
 
mg/L µM 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A 
AMT-type  
          
AMT 
0.16-1.3 
 (Elliott and Evans, 2014) 
0.9-7.5 
336 (± 
0.8) 
3.2 (± 
0.1) 
159 (± 
0.06) 
  62 (± 20) 46 (± 12) 
292 (± 
91) 
163 (± 
5.8) 
2-Me-AMT 
0.16-1.3 
 (Elliott and Evans, 2014) 
0.8-6.9 
138 (± 
0.5) 
74 (± 51)   
  
56 (± 14) 
 
166 (± 77) 
4-MeO-AMT 
0.16-1.3 
 (Elliott and Evans, 2014) 
0.8-6.8 
7.7 (± 
0.9) 
89 (± 22)  
 
  
14 (± 
2.2 ) 
169 (± 
20) 
136 (± 76) 
5-F-AMT 
0.16-1.3 
 (Elliott and Evans, 2014) 
0.8-6.8 
170 (± 
8.8) 
187 (± 
27) 
  
86 (± 
0.06) 
 19 (± 9) 
214 (± 
79) 
 
5-F-2-Me-AMT 
0.16-1.3 
 (Elliott and Evans, 
2014) 
0.8-6.3 
126 (± 
0.07) 
 64 (± 14)   
300 (± 
21) 
15 (± 5)  217 (± 9) 
5-Cl-AMT 
0.16-1.3 
 (Elliott and Evans, 2014) 
0.8-6.2 
25 (± 
0.07) 
101 (± 
27) 
206 (± 
45) 
  
235 (± 
53) 
11 (± 3) 
181 (± 
30) 
205 (± 46) 
5-Me-AMT 
0.16-1.3 
 (Elliott and Evans, 
2014) 
0.8-6.9 22 (± 17) 
395 (± 
48) 
221 (± 
85) 
  
268 (± 
103) 
34 (± 13) 
115 (± 
14) 
317 (± 46) 
6-F-AMT 
0.16-1.3 
 (Elliott and Evans, 2014) 
0.8-6.7 
36 (± 
0.02) 
2.7 (± 
0.9) 
345 (± 
74) 
   53 (± 19) 
210 (± 
6.4) 
 
7-Me-AMT 
0.16-1.3 
 (Elliott and Evans, 
2014) 
0.8-6.9 54 (± 8.4) 
261 (± 
164) 
85 (± 7.2)   
318 (± 
94) 
71 (± 22) 
181 (± 
74) 
337 (± 70) 
DALT-type            
DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.6-7.1 
0.4 (± 
0.1) 
 
175 (± 
105) 
   2.6 (± 2) 91(± 12) 90 (± 12) 
5-F-DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.5-6.6 
0.9 (± 
0.5) 
 64 (± 10)  
109 (± 
5.6) 
200 (± 
13)  
4.8 (± 
0.9) 
390 (± 
8.7) 
75 (± 8.1) 
5-F-2-Me-DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.5-6.3 
0.8 (± 
0.3) 
 30 (± 1.4) 
199 (± 
3.3) 
63 (± 2.2) 33 (± 1.8) 
0.8 (± 
0.1) 
146 (± 
74) 
31 (± 3.1) 
5-Cl-DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.5-6.2 
0.3 (± 
0.009) 
 39 (± 12) 
190 (± 
52) 
31 (± 0.8) 36 (± 11) 
1.2 (± 
0.3) 
135 (± 
76) 
59 (± 23) 
5-Br-DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.4-5.3 0.8 (± 0.2)  52 (± 0.6) 176 (± 15) 23 (± 0.04) 52 (± 3.4) 2.5 (± 0.4) 122 (± 58) 60 (± 16) 
5-Me-DALT 
0.14-1.7 
 (Elliott and Evans, 
2014; Tanaka et al., 
2006; Wilson et al., 
2005) 
0.6-6.7 
0.7 (± 
0.5) 
 
138 (± 
14) 
 77 (± 13) 
156 (± 
3.4) 
3.8 (± 
0.7) 
11 (± 12) 67 (± 9.8) 
5-MeO-DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.5-6.3 
0.4 (± 
0.1) 
 
0.8 (± 
0.9) 
  
111 (± 
128) 
13 (± 11) 20 (± 14) 114 (± 36) 
6-F-DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.5-6.6 
0.3 (± 
0.02) 
 48 (± 16) 75 (± 84) 71 (± 8.4) 48 (± 14) 
0.3 (± 
0.05) 
48 (± 55) 42 (± 14) 
7-Me-DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.6-6.7 
0.1 (± 
0.03) 
 
135 (± 
45) 
 
159 (± 
31) 
261 (± 
79) 
0.2 (± 
0.2) 
238 (± 
48) 
84 (± 12) 
5,6-MD-DALT 
 (Dinger et al., 
2014c) 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.5-6 
0.3 (± 
0.2) 
 26 (± 15)  58 (± 0.7) 58 (± 17) 
0.4 (± 
0.3) 
 15 (± 0.1) 
4,5-ED-DALT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.5-5.7 
0.1 (± 
0.01) 
139 (± 
121) 
66 (± 28) 17 (± 20) 
116 (± 
9.2) 
55 (± 26) 
2.9 (± 
0.8) 
168 (± 
20) 
 
DMT-type            
DMT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.7-9          
5-MeO-2-Me-
DMT 
0.14-1.7 
 (Elliott and Evans, 2014; 
Tanaka et al., 2006; 
Wilson et al., 2005) 
0.6-7.3 
198 (± 
107) 
 
377 (± 
80) 
   57 (± 1) 20 (± 6)  
DiPT-type            
4-HO-DiPT 
0.14-1.7 
 (Wilson et al., 2005) 
 (Tanaka et al., 
2006) 
0.5-6.5 
297 (± 
3.3) 
450 (± 
175) 
271 (± 
78) 
  88 (± 23) 
9.6 (± 
2.4) 
60 (± 6.2) 
115 (± 
2.2) 
5-MeO-2-Me-
DiPT 
0.14-1.7 
 (Wilson et al., 2005) 
 (Tanaka et al., 2006) 
0.5-5.9   
135 (± 
27) 
  
122 (± 
20) 
57 (± 
0.01) 
114 (± 
83) 
198 (± 34) 
Known 
inhibitors 
     
 
     
Fluvoxamine 
0.06-0.23 
 (Schulz et al., 2012) 
0.2-0.7 
 
0.2 
 (Brosen et 
al., 1993) 
  
 
     
Amiodarone 
0.5-2.5 
 (Schulz et al., 2012) 
0.7-3.9 
 
86 
 (Kobayashi 
et al., 1998) 
  
 
     
Efavirenz 
> 1 
 (Schulz et al., 2012) > 3.2 
 
  
6 
 (Xu and 
Desta, 
2013) 
 
     
Gemfibrozil 
25 
 (Schulz et al., 2012)     
91 
 (Wang et 
al., 2002) 
     
Fluconazole 
1-5 
 (Schulz et al., 2012) 
4.9-16.3 
 
   
 30.3 
 (Niwa et 
al., 2005) 
    
Chloramphenicol 
5-10 
 (Schulz et al., 2012) 
15.5-31 
 
   
 
 
32 
 (Park et al., 
2003) 
   
Fluoxetine 
0.12-0.5 
 (Schulz et al., 2012) 0.4-1.6 
 
   
 
  
8.2 (Ki) 
 (Ewald and 
Maurer, 
2008) 
  
Paroxetine 
0.01-0.05 
 (Schulz et al., 2012) 
0.03-
0.15 
 
   
 
  
2.85 
 (Bertelsen 
et al., 2003) 
  
Clarithromycin 
2.5-4  
 (Schulz et al., 2012) 
3.3-5.4 
 
   
 
    
116 
 (Burt et al., 
2010) 
Saquinavir 
0.1-5 
 (Schulz et al., 2012) 
0.15-0.4 
 
   
 
    
11.5 
 (von Moltke 
et al., 1998) 
in vitro  
Probe inhibitors 
(Dinger et al., 
2014b) 
 
    
 
     
Alpha-
naphthoflavone 
 
 0.04   
 
     
Tranylcypromine 
< 0.05 
 (Schulz et al., 2012) 
< 0.4 
 
 0.4  
 
     
Sertraline 0.001-0.01 
 (Schulz et al., 2012) 
0.003-
0.03   1 
 
     
Trimethoprim 
1.5-2.5 
 (Schulz et al., 2012) 5-8.6    17      
Sulfaphenazole 
 
    
 
0.4     
Fluconazole 
0.001-0.01 
 (Schulz et al., 2012) 
4.9-16.3 
 
   
 
 17    
Quinidine 
1-5 
 (Schulz et al., 2012) 3.1-15.4    
 
  0.1   
Clomethiazole 
0.01-0.05 
 (Schulz et al., 2012) 
0.6-31 
 
   
 
   10.9  
Verapamil 
0.1-0.25 
 (Schulz et al., 2012) 
0.04-
0.55 
 
   
 
    22 
  
Table 3 
Validation data for caffeine quantification 
Validation parameter QC low QC high 
Recovery, % (CV %) 59 (35) 44 (18) 
Matrix effect, % (CV %) 59 (15) 87 (14) 
Process efficiency, % (CV %) 36 (33) 38 (26) 
Accuracy bias, % - 10.7 7.1 
Precision (RSD %) 29.6 31.2 
 
 
Table 4  
Kinetic parameters of the in vivo metabolism of caffeine for control group, positive group, and test group, administered doses and drugs 
Study group Administered drug Dose, mg/kg BM Kinetic parameter of caffeine 
 
  AUC, h*mg/L Cmax, mg/L tmax, h 
Control 
caffeine 10 
36 (± 8) 4.2 (± 0.5) 2.5 (± 0.7) 
- - 
Positive 
caffeine 10 
103 (± 31) 20 (± 10) 1.9 (± 0.4) 
fluvoxamine 6 
Test 
caffeine 10 
307 (± 3) 18.5 (± 0.5) 2.3 (± 0.3) 
5-MeO-DALT 0.6 
 
 
